#USA #FDA Approval #Minneapolis #EmpNia #eMotus

EmpNia's Groundbreaking eMotus™ Receives FDA Clearance

In a significant advancement for cancer treatment, EmpNia, a notable player in medical device innovation, has secured FDA clearance to market its transformative product, eMotus™. This system is specifically designed to tackle the complexities of managing respiratory motion during image-guided radiation therapy (IGRT), a crucial yet challenging aspect of oncological care.

The management of respiratory motion is critical in delivering safe and accurate IGRT, but traditional solutions often present several hurdles. Clinicians have faced difficulties with existing systems, which can be cumbersome, disruptive to clinical workflows, and sometimes incompatible across various modalities. Moreover, these previous methods can be prohibitively expensive, ranging from installation to maintenance costs.

eMotus™, however, is poised to change this landscape. The innovative system features a disposable sensor pad paired with intuitive software that allows for quick setup and effective motion tracking, ensuring that radiation therapy can be conducted with greater accuracy. This simplicity means that the system can be installed rapidly, typically within hours, providing hospitals with the ability to improve patient outcomes without the need for costly infrastructure changes.

Dr. Cliff Robinson, Chief Medical Officer of EmpNia, emphasized the importance of eMotus™ in clinical settings: "The challenge of managing respiratory motion across patient types, during both imaging and treatment, has complicated many clinicians' workflows. Our solution not only simplifies this process but is also universally compatible, allowing care teams to focus on delivering care instead of managing technology."

The eMotus™ system is uniquely designed for flexibility and usability. It accommodates all types of imaging and therapy equipment, allowing clinics to seamlessly adopt this state-of-the-art technology without financial strain. Manojeet Bhattacharya, the founder and CEO of EmpNia, stated, "Radiation oncology teams should not have to make difficult choices between precision and operational practicality. The FDA clearance of eMotus™ facilitates a balance between these necessities, as it is engineered for ease of use, broad compatibility, and cost efficiency through its innovative sensor pad model."

Founded in 2020, EmpNia was born from Bhattacharya's notable experience in medical imaging and technology development. His journey revealed a pressing need for effective motion management solutions within radiation therapy, prompting the inception of eMotus™. The product has already demonstrated improvements in workflow efficiency, ease of setup, and accurate motion tracking in early evaluations, marking a significant leap forward in patient care.

The eMotus™ system is specifically tailored for radiation oncology professionals who are tasked with monitoring and managing respiratory motion in patients undergoing treatment. By facilitating a more organized approach, eMotus™ not only enhances the patient experience but also alleviates the burdens placed on clinical teams.

As EmpNia Inc. continues to pave the way in medical device innovation, the Boston-based company’s commitment to delivering practical solutions highlights its dedication to enhancing patient care and treatment accuracy. With eMotus™ now available for use across the U.S., the future of precision radiation therapy appears more promising than ever.

For further details about EmpNia and its pioneering innovations, visit www.empnia.com.